GET DAILY SIGNALSVerastem (VSTM) Analyst Targets Signal Potential +108% Upside
Key Takeaways
- The central $17 stock price target is the arithmetic mean of nine current analyst price targets, rounded to a clean level from an underlying average of roughly $17.10.
- With shares recently trading near $8.20, reaching $17 would require a rise of about 108%, a very large move from current levels.
- Individual analyst price targets span a wide range from roughly $13 to $24, with nearly all firms carrying Buy or Strong Buy ratings on the stock.
- The strongest supporting factors are the commercial launch of the avutometinib and defactinib combination and an early-stage pipeline targeting KRAS G12D-mutant cancers.
- The biggest risks are persistent net losses, a crowded KRAS oncology field, and the execution and dilution risks common to development-stage biotechs.
- For more detail on Verastem's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
- Discover Trending AI Robots to see how automated AI strategies are approaching opportunities across the market.
Analyst Price Targets and Consensus View
Verastem, Inc. (VSTM) is an oncology biopharmaceutical company focused on therapies for RAS and MAPK pathway-driven cancers. It is a stock, not an exchange-traded fund, so this analysis centers on equity analyst price targets rather than fund holdings or index methodology.
Reviewing current, attributable analyst targets yields nine valid figures. The most recent revisions cluster in a range of roughly $13 to $24. At the high end, BTIG carries a $24 target, followed by Alliance Global Partners at $22 and H.C. Wainwright at $20. In the middle, RBC Capital sits at $18, Guggenheim and Benchmark at $14, and Jefferies and Mizuho at $13. The arithmetic mean of these nine targets is about $17.10, which rounds to a $17 central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Consensus leans decidedly bullish, with virtually all covering firms at Buy or Strong Buy. That said, the spread between $13 and $24 reflects genuine disagreement about how quickly the commercial launch will translate into durable value. Analysts emphasize the FDA approval of the avutometinib plus defactinib combination for KRAS-mutant recurrent low-grade serous ovarian cancer as the central thesis, while lower targets embed more caution around competition and cash burn.
Current Market Position and Path Toward the Target
Shares recently traded near $8.20, having pulled back roughly 10% in a single session after third-quarter results and then stabilizing. Reaching $17 would require an increase of approximately 108%, a very large move that is consistent with the wide dispersion in analyst targets rather than a near-term repricing.
The path depends on execution rather than a single valuation re-rating. Verastem reported third-quarter revenue of about $24 million against a GAAP net loss of roughly $75 million, reflecting the early stage of its commercial rollout. Because the company remains unprofitable, conventional P/E (price-to-earnings) valuation does not apply, and the stock is driven primarily by launch trajectory, clinical catalysts, and sentiment around the KRAS pipeline.
What Could Support a Move Toward the Target
The clearest support is commercial traction. The avutometinib and defactinib combination gives Verastem a first-to-market position in KRAS-mutant low-grade serous ovarian cancer, a niche with limited competition and meaningful unmet need. Revenue is ramping from a small base, with full-year 2026 estimates pointing to a sharp year-over-year increase.
A second pillar is the pipeline, particularly VS-7375 for KRAS G12D-mutant solid tumors, which analysts view as optionality beyond the initial launch. Positive clinical readouts in a large, historically difficult-to-drug target could justify materially higher valuation. A strong cash position and a consensus of Buy ratings also provide a supportive backdrop.
What Could Prevent the Target From Being Reached
The principal obstacle is profitability. Verastem continues to post substantial net losses, and reaching $17 implies a market capitalization far above today's level without the earnings support that typically anchors such valuations. If the launch ramps more slowly than modeled, or if gross-to-net dynamics and competition compress the opportunity, the stock could struggle to re-rate.
The KRAS space is also becoming crowded, with larger competitors advancing programs across multiple mutations. Pipeline setbacks for VS-7375, dilution from future financings, and general risk-off sentiment in small-cap biotechnology could each pressure the shares. Several analysts trimmed targets in 2026, reflecting exactly these concerns.
Technical Levels and Market Structure
The stock's 52-week range runs from roughly $3.43 to about $10.82. The recent pullback left shares below the $10 area, which now acts as overhead resistance, while the single-digit $8 zone has functioned as a short-term support area. A durable move toward the $17 target would first require reclaiming and holding above the prior highs near $10.82, a level that has repeatedly capped rallies.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms vary. Investors should watch quarterly revenue and launch metrics for the avutometinib and defactinib combination, updates on the VS-7375 program, and any changes to cash runway or financing plans. Data readouts in the KRAS G12D program, analyst target revisions, and broader biotech risk appetite are the most likely near-term drivers.
Using AI Tools for Ongoing Monitoring
Tickeron's AI Daily Buy/Sell Signals have become a regular part of my workflow when following names like this. The system scans thousands of stocks in real time and flags shifts in technical behavior or momentum, which helps me stay on top of potential turning points without having to monitor every chart manually. From what I see, these signals add useful context around volatile development-stage names where news flow can move quickly.
Final Assessment
The $17 central target for Verastem (VSTM) is the arithmetic mean of nine analyst price targets ranging from roughly $13 to $24. Because the stock trades near $8.20, the required move of about 108% is very large, and the wide target range underscores meaningful disagreement about execution. Commercial momentum for the avutometinib and defactinib combination and the KRAS pipeline are the strongest supports, while persistent losses, a competitive oncology landscape, and dilution risk are the primary obstacles. Whether the shares approach $17 will depend on launch trajectory, clinical data, and analyst revisions in the quarters ahead, and no outcome is guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
VSTM in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where VSTM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 60 cases where VSTM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 73 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for VSTM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
VSTM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.498). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops drugs
Industry Biotechnology
Advertisement